AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25538270 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 107
Study 25538270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 23799454 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (4th hour after PEG placement)
Number of subjects: 69
Study 21892006 — intervention group
Group type: EXPERIMENTAL
Intervention: HB-AS02
Number of subjects: 151
Study 21892006 — intervention group
Group type: COMPARATOR
Intervention: HB-AS04
Number of subjects: 151
Study 19352339 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adalimumab 40 mg every other week (e.o.w.)
Number of subjects: 778
Study 19352339 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adalimumab 40 mg every week
Number of subjects: 778
Study 19352339 — intervention group
Group type: COMPARATOR
Intervention: Induction dosing followed by reinitiation of adalimumab
Number of subjects: 778
Study 17873301 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) therapy
Number of subjects: 0
Study 17873301 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life improvement
Number of subjects: 0
Study 15226773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (NI) - intensive, individualised nutrition counselling by a dietitian using a standard protocol and oral supplements if required
Number of subjects: 60
Study 15226773 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) - general advice and nutrition booklet
Number of subjects: 60
Study 15226773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (NI)
Number of subjects: 60
Study 11851743 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections
Number of subjects: 0
Study 11851743 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9591224 — intervention group
Group type: COMPARATOR
Intervention: tolcapone 200 mg with immediate-release levodopa/carbidopa formulations
Number of subjects: 30
Study 9591224 — intervention group
Group type: COMPARATOR
Intervention: tolcapone 200 mg with controlled-release levodopa/carbidopa formulation
Number of subjects: 30
Study 9591224 — intervention group
Group type: COMPARATOR
Intervention: tolcapone 200 mg
Number of subjects: 30
Study 9591224 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 7908624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 MU thrice weekly) for one year
Number of subjects: 60
Study 7908624 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 60
Study 7908624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 60
Study 2892388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 537
Study 2892388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol and non-beta-blocker treatment
Number of subjects: 537
Study 2892388 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 537
Study 2892388 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker-based therapy
Number of subjects: 537
Study 31750855 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine ω‐3 fatty acid, 1 g daily (including eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg)
Number of subjects: 25871
Study 31750855 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 25871
Study 31750855 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine ω‐3 fatty acid, 1 g daily
Number of subjects: 25871
Study 31752864 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm using artificial neural network (TensorFlow) trained on multi-center neuropsychological test data
Number of subjects: 14926
Study 28738895 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy
Number of subjects: 19
Study 28738895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham manipulation)
Number of subjects: 19
Study 28738895 — intervention group
Group type: COMPARATOR
Intervention: Control (continued usual but non‐manual management)
Number of subjects: 19
Study 25843054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (1% THC)
Number of subjects: 16
Study 25843054 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose (4% THC)
Number of subjects: 16
Study 25843054 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (7% THC)
Number of subjects: 16
Study 25843054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23658394 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal capsular polysaccharide, CRM197 conjugate vaccine (PCV7)
Number of subjects: 0
Study 23658394 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 0
Study 21237188 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of lutein and 1 mg of zeaxanthin daily
Number of subjects: 121
Study 21237188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 19686995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) preparation (90 mL in divided doses)
Number of subjects: 276
Study 19686995 — intervention group
Group type: COMPARATOR
Intervention: High-dose bisacodyl preparation (6 tablets of 5mg bisacodyl) plus water lavage (2 L of water)
Number of subjects: 276
Study 17876336 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-positive tumours
Number of subjects: 54
Study 17876336 — intervention group
Group type: COMPARATOR
Intervention: EGFR-negative tumours
Number of subjects: 54
Study 15032409 — intervention group
Group type: EXPERIMENTAL
Intervention: Survcard (Group I)
Number of subjects: 58
Study 15032409 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostic methods (Group II)
Number of subjects: 58
Study 11277449 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal detection paradigm with audio signals
Number of subjects: 55
Study 9530159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 80 mg/kg
Number of subjects: 49
Study 9530159 — intervention group
Group type: COMPARATOR
Intervention: Aqueous 5% glucose (control)
Number of subjects: 49
Study 9530159 — intervention group
Group type: COMPARATOR
Intervention: Graft liver (no DCA)
Number of subjects: 49
Study 9530159 — intervention group
Group type: COMPARATOR
Intervention: Control liver (no DCA)
Number of subjects: 49
Study 8067224 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Safety Yellow
Number of subjects: 200
Study 8067224 — intervention group
Group type: COMPARATOR
Intervention: Super Safety Clear
Number of subjects: 200
Study 8067224 — intervention group
Group type: COMPARATOR
Intervention: PVC-tubes
Number of subjects: 200
Study 8067224 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 200
Study 8067224 — intervention group
Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 200
Study 2499527 — intervention group
Group type: EXPERIMENTAL
Intervention: CHPP‐M (continuous hyperthermic peritoneal perfusion with mitomycin C)
Number of subjects: 82
Study 2499527 — intervention group
Group type: COMPARATOR
Intervention: Control (no CHPP‐M treatment)
Number of subjects: 82
Study 4881070 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Number of subjects: 0
Study 4881070 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin
Number of subjects: 0
Study 4881070 — intervention group
Group type: EXPERIMENTAL
Intervention: Melarsonyl potassium (Mel W)
Number of subjects: 0
Study 31272488 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 480
Study 31272488 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 480
Study 31272488 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 480
Study 28862513 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GCs) at baseline
Number of subjects: 819
Study 28862513 — intervention group
Group type: COMPARATOR
Intervention: No glucocorticoids (GCs) at baseline
Number of subjects: 819
Study 28862513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoids (highest tertile)
Number of subjects: 819
Study 28862513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoids (lowest tertile)
Number of subjects: 819
Study 26507607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A (nutrition education for children)
Number of subjects: 212
Study 26507607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B (education for teachers)
Number of subjects: 212
Study 26507607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 212
Study 23732262 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 61
Study 23732262 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 61
Study 21707127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Number of subjects: 162
Study 21707127 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 162
Study 20592050 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial
Number of subjects: 45
Study 20592050 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals' involvement in the trial
Number of subjects: 45
Study 18320867 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg/day
Number of subjects: 14
Study 18320867 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day plus esterified conjugated estrogens 0.312 mg/day
Number of subjects: 14
Study 16252374 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen intervention implemented in 24-hour care with a 4-day in-house training program and follow-up activities.
Number of subjects: 129
Study 16252374 — intervention group
Group type: COMPARATOR
Intervention: Usual care in control wards.
Number of subjects: 129
Study 12009719 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 155
Study 10352372 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7594334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg q.d. (n = 10)
Number of subjects: 20
Study 7594334 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg b.i.d. (n = 10)
Number of subjects: 20
Study 2179066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg after evening meal
Number of subjects: 0
Study 2179066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg before evening meal
Number of subjects: 0
Study 2179066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2179066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg with snacks allowed
Number of subjects: 0
Study 2179066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg with snacks forbidden
Number of subjects: 0
Study 2179066 — intervention group
Group type: COMPARATOR
Intervention: Placebo with snacks
Number of subjects: 0
Study 2179066 — intervention group
Group type: COMPARATOR
Intervention: Placebo without snacks
Number of subjects: 0
Study 6783419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine administration
Number of subjects: 0
Study 6783419 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid administration
Number of subjects: 0
Study 6783419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 0
Study 6783419 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol diet
Number of subjects: 0
Study 6783419 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects vs. patients heterozygous for familial hypercholesterolaemia
Number of subjects: 0
Study 31526892 — intervention group
Group type: EXPERIMENTAL
Intervention: VSP 5
Number of subjects: 156
Study 31526892 — intervention group
Group type: EXPERIMENTAL
Intervention: VSP 7
Number of subjects: 156
Study 31526892 — intervention group
Group type: EXPERIMENTAL
Intervention: VSP 2
Number of subjects: 156
Study 31526892 — intervention group
Group type: EXPERIMENTAL
Intervention: VSP 6
Number of subjects: 156
Study 31526892 — intervention group
Group type: EXPERIMENTAL
Intervention: VSP 4
Number of subjects: 156
Study 31526892 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual diameter measurements
Number of subjects: 156
Study 28438283 — intervention group
Group type: EXPERIMENTAL
Intervention: Music stimulation (n = 204)
Number of subjects: 409
Study 28438283 — intervention group
Group type: COMPARATOR
Intervention: No music (n = 205)
Number of subjects: 409
Study 25567841 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% of the standard dose of IPV intradermally
Number of subjects: 231
Study 25567841 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% of the standard dose intradermally
Number of subjects: 231
Study 25567841 — intervention group
Group type: COMPARATOR
Intervention: full standard dose intramuscularly
Number of subjects: 231
Study 25567841 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% of the standard dose intramuscularly
Number of subjects: 231
Study 23212720 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264
Study 23212720 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted warfarin
Number of subjects: 14264
Study 23212720 — intervention group
Group type: EXPERIMENTAL
Intervention: R(2)CHADS(2) model including creatinine clearance
Number of subjects: 14264
Study 23212720 — intervention group
Group type: EXPERIMENTAL
Intervention: R(2)CHADS(2) model validated in external population
Number of subjects: 14264
Study 21887214 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (A/L)
Number of subjects: 19
Study 21887214 — intervention group
Group type: EXPERIMENTAL
Intervention: atovaquone-proguanil (A/P)
Number of subjects: 19
Study 19454737 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers
Number of subjects: 464000
Study 19454737 — intervention group
Group type: EXPERIMENTAL
Intervention: Other blood pressure lowering drugs
Number of subjects: 464000
Study 19454737 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure reduction of 10 mm Hg systolic or 5 mm Hg diastolic
Number of subjects: 464000
Study 19454737 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 464000
Study 19454737 — intervention group
Group type: EXPERIMENTAL
Intervention: Three drugs at half standard dose
Number of subjects: 464000
Study 19454737 — intervention group
Group type: EXPERIMENTAL
Intervention: Other blood pressure lowering drugs (excluding non-cardioselective β blockers)
Number of subjects: 464000
Study 17574482 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 5 ml of 5% NaOCl + 2.5 ml of 3.6% H(2)O(2)
Number of subjects: 40
Study 17574482 — intervention group
Group type: COMPARATOR
Intervention: Group B: 5 ml of 5% NaOCl + 2.5 ml of 17% ethylenediamine tetraacetic acid
Number of subjects: 40
Study 15043765 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, sertindole, amisulpride, aripiprazole)
Number of subjects: 0
Study 15043765 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation antipsychotics
Number of subjects: 0
Study 15043765 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0
Study 11703949 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at <2 hours
Number of subjects: 1232
Study 11703949 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at >=2 hours
Number of subjects: 1232
Study 11703949 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at 2 to <4 hours
Number of subjects: 1232
Study 11703949 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at 4 to <6 hours
Number of subjects: 1232
Study 11703949 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with reperfusion at >6 hours
Number of subjects: 1232
Study 11703949 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) with later reperfusion
Number of subjects: 1232
Study 9628595 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatic resection
Number of subjects: 556
Study 9628595 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 556
Study 9628595 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (crossover to surgery)
Number of subjects: 556
Study 7829035 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hospice care for patients living alone
Number of subjects: 34
Study 7829035 — intervention group
Group type: COMPARATOR
Intervention: Regular hospice care
Number of subjects: 34
Study 3121836 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h infusion of phosphate
Number of subjects: 14
Study 3121836 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h infusion of calcium
Number of subjects: 14
Study 3121836 — intervention group
Group type: COMPARATOR
Intervention: Not infused phosphate
Number of subjects: 14
Study 3121836 — intervention group
Group type: COMPARATOR
Intervention: Not infused calcium
Number of subjects: 14
Study 29659754 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus oseltamivir initiated within 24 hours of enrollment (group B)
Number of subjects: 1107
Study 29659754 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (group A)
Number of subjects: 1107
Study 29659754 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus oseltamivir (group B)
Number of subjects: 1107
Study 27070386 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 60
Study 27070386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 60
Study 27070386 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 25391865 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 120 kVp with 350 mgI/ml iodinated contrast agent
Number of subjects: 45
Study 25391865 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 100 kVp with 350 mgI/ml iodinated contrast agent
Number of subjects: 45
Study 25391865 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 100 kVp with 270 mgI/ml iodinated contrast agent
Number of subjects: 45
Study 25391865 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 45
Study 25391865 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 45
Study 25391865 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 45
Study 23868011 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (3 additional years of treatment)
Number of subjects: 634
Study 23868011 — intervention group
Group type: COMPARATOR
Intervention: Nil (no additional treatment)
Number of subjects: 634
Study 16015270 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter (40 g daily for 4 weeks)
Number of subjects: 19
Study 16015270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese (40 g daily for 4 weeks)
Number of subjects: 19
Study 16015270 — intervention group
Group type: COMPARATOR
Intervention: Run-in period (less saturated fat)
Number of subjects: 19
Study 11849857 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Angioplasty (PA)
Number of subjects: 1375
Study 11849857 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 1375
Study 11849857 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >70
Number of subjects: 1375
Study 11849857 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1375
Study 11849857 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior location
Number of subjects: 1375
Study 11849857 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment >2 h after symptoms onset
Number of subjects: 1375
Study 10366082 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 1%
Number of subjects: 228
Study 10366082 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 4%
Number of subjects: 228
Study 10366082 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 1% (long-term use)
Number of subjects: 228
Study 10366082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% (long-term use)
Number of subjects: 228
Study 7741336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tornalate (38% ethanol)
Number of subjects: 3
Study 7741336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronkometer (30% ethanol)
Number of subjects: 3
Study 7741336 — intervention group
Group type: EXPERIMENTAL
Intervention: Alupent (0% ethanol)
Number of subjects: 3
Study 7741336 — intervention group
Group type: COMPARATOR
Intervention: Blood ethanol levels
Number of subjects: 3
Study 1665182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril-hydrochlorothiazide (L/HCTZ)
Number of subjects: 286
Study 6109543 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggro
Number of subjects: 0
Study 6109543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30063558 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal-sparing ILM peeling (FS group)
Number of subjects: 38
Study 30063558 — intervention group
Group type: COMPARATOR
Intervention: Complete ILM peeling (CP group)
Number of subjects: 38
Study 30063558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 28651150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) for 4 weeks
Number of subjects: 33
Study 28651150 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 33
Study 25881049 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (transfuse if haemoglobin concentration <7.5 g/dl)
Number of subjects: 2000